Full-Time

Senior Manager Regulatory Affairs US & Canada Strategy Lead

Therapeutic Neuroscience

Posted on 8/3/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$124.5k - $236.5k/yr

+ Long-term incentive program

Florham Park, NJ, USA

Hybrid

Three days or fewer on-site per week implied by the hybrid designation.

Bachelor's, Master's, PharmD, PhD

Category
Legal

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • An advanced degree, such as a PharmD, PhD, or Master of Science, or regulatory certification, with a minimum of 5 years of regulatory, research and development, or equivalent industry-related experience.
  • Demonstrated negotiation and problem-solving skills and the ability to build consensus.
  • Effective written and oral communication skills within Regulatory and across the organization, including the ability to deliver challenging messages while maintaining business relationships.
  • Experience implementing affiliate regulatory strategies.
  • Experience working in a complex and matrix environment.
  • Experience interfacing with government regulatory agencies.
Responsibilities
  • Develop and implement United States and Canada regulatory strategic and tactical planning for assigned marketed or development products.
  • Ensure regulatory strategies defined within the Global Regulatory Product Team are effectively implemented and maintained in line with changing regulatory and business needs.
  • Identify and gather data needed to support filings, responses to inquiries, and registration maintenance for products developed, manufactured, or distributed to meet United States and Canada regulatory requirements.
  • Manage products with multiple driver indications within a therapeutic area and support the manager or Global Regulatory Lead in developing and executing regulatory strategy.
  • Serve as a Health Authority liaison and interface with the Food and Drug Administration for meetings and teleconferences.
  • Coordinate the preparation and completion of Food and Drug Administration meeting briefing packages and responses.
  • Advise internal customers contributing to regulated communications on Regulatory and Food and Drug Administration issues, including Public Affairs, Clinical Development, Legal, and Commercial.
  • Function independently in negotiation and decision-making for project-related issues with cross-functional impact.
  • Assist in training junior staff members.
  • Prepare and review regulatory submissions consistent with United States and Canada regulatory requirements and guidelines.
  • Ensure complete and timely responses to Health Authorities during application review.
  • Support the regulatory submission and approval process.
  • Apply regulatory and technical knowledge of government regulations and skills across therapeutic areas.
  • Recommend and implement changes to difficult projects based on United States and Canada government regulations, guidances, corporate policies, and management considerations.
  • Present pertinent regulatory information to appropriate cross-functional areas.
  • Operate in compliance with regulations, company policies, procedures, and guidance in alignment with regulatory product strategy and the Quality Dossier Program.
Desired Qualifications
  • Advanced degree and/or certifications or direct experience with pharmaceutical regulatory activities.
  • United States or Canada regulatory experience.
  • Global regulatory experience.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Etentamig hit 74% response and 60% progression-risk reduction on September 3, 2026.
  • FDA approved Decnupaz on May 27, 2026, creating AbbVie’s first blood-cancer ADC.
  • WCLC 2026 data showed ABBV-1480 and ABBV-706 strength across lung-cancer programs.

What critics are saying

  • Imbruvica sales fell 29.4% in Q2 2026, exposing oncology erosion.
  • FDA declined trenibotE in April 2026; manufacturing fixes pushed approval into 2027.
  • CMS Botox price controls and AbbVie’s February 2026 lawsuit threaten aesthetics margins.

What makes AbbVie unique

  • AbbVie’s 2026 engine combines Skyrizi, Rinvoq, oncology, and aesthetics.
  • Apogee acquisition deepens AbbVie’s inflammatory pipeline beyond Humira replacement products.
  • AbbVie commercializes injectable biologics and ADCs across specialty, outpatient, and hospital settings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 3rd, 2026
AbbVie's etentamig shows 74% response rate in cancer trial, beating standard treatment by 28 percentage points

AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Aug 29th, 2026
AbbVie acquires Apogee for $10.9B as Eli Lilly's GLP-1 drugs drive 45% revenue surge

AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion as it works to diversify beyond its core immunology portfolio. The pharmaceutical giant reported revenue of nearly $61.2 billion in FY 2025, up roughly 8.7% year-on-year, with Skyrizi and Rinvoq accounting for about 42% of sales. Eli Lilly achieved sharper growth, with revenue reaching nearly $65.2 billion in FY 2025, a 45% increase driven by GLP-1 drugs Mounjaro and Zepbound. These therapies represented roughly 56% of total revenue. Net income was approximately $20.6 billion. AbbVie's balance sheet shows a debt-to-equity ratio of negative 21x, whilst Eli Lilly's stands at roughly 1.6x. Free cash flow was nearly $17.8 billion for AbbVie and close to $9.0 billion for Eli Lilly.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 25th, 2026
AbbVie's oncology sales fall 2.4% to $1.65B as Imbruvica drops 29%

AbbVie's oncology revenues declined 2.4% year over year to $1.65 billion in Q2 2026, pressured by blood cancer drug Imbruvica, whose sales fell 29.4% to $532 million due to competitive pressure and IRA-driven pricing changes. However, growth from other products partially offset this decline. Venclexta sales rose nearly 10% to $771 million, driven by strong demand in chronic lymphocytic leukaemia. Newer products showed robust growth, with Elahere up 32% to $211 million and Epkinly increasing 48% to $103 million. Lung cancer therapy Emrelis exceeded expectations as physicians became more familiar with c-Met testing. The quarter also marked the launch of Decnupaz, AbbVie's first marketed antibody drug conjugate in haematology, following recent FDA approval for blastic plasmacytoid dendritic cell neoplasm.

INACTIVE